These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 22636820)

  • 21. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS.
    Shimizu M; Furuichi K; Toyama T; Funamoto T; Kitajima S; Hara A; Ogawa D; Koya D; Ikeda K; Koshino Y; Kurokawa Y; Abe H; Mori K; Nakayama M; Konishi Y; Samejima KI; Matsui M; Yamauchi H; Gohda T; Fukami K; Nagata D; Yamazaki H; Yuzawa Y; Suzuki Y; Fujimoto S; Maruyama S; Kato S; Naito T; Yoshimura K; Yokoyama H; Wada T;
    Clin Exp Nephrol; 2018 Apr; 22(2):377-387. PubMed ID: 28889347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
    Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
    Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.
    de Boer IH; Rue TC; Cleary PA; Lachin JM; Molitch ME; Steffes MW; Sun W; Zinman B; Brunzell JD; ; White NH; Danis RP; Davis MD; Hainsworth D; Hubbard LD; Nathan DM
    Arch Intern Med; 2011 Mar; 171(5):412-20. PubMed ID: 21403038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Glycemic Markers in Chronic Hemodialysis Using Continuous Glucose Monitoring.
    Divani M; Georgianos PI; Didangelos T; Iliadis F; Makedou A; Hatzitolios A; Liakopoulos V; Grekas DM
    Am J Nephrol; 2018; 47(1):21-29. PubMed ID: 29275415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters.
    Al-Rubeaan K; Siddiqui K; Alghonaim M; Youssef AM; AlNaqeb D
    Ann Saudi Med; 2018; 38(1):46-56. PubMed ID: 29295969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
    Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
    Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
    J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.
    Oellgaard J; Gæde P; Rossing P; Persson F; Parving HH; Pedersen O
    Kidney Int; 2017 Apr; 91(4):982-988. PubMed ID: 28187983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
    JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study.
    Chan JC; So WY; Yeung CY; Ko GT; Lau IT; Tsang MW; Lau KP; Siu SC; Li JK; Yeung VT; Leung WY; Tong PC;
    Diabetes Care; 2009 Jun; 32(6):977-82. PubMed ID: 19460913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum albumin-adjusted glycated albumin reflects glycemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysis.
    Fukami K; Shibata R; Nakayama H; Yamada K; Okuda S; Koga M
    J Diabetes Complications; 2015; 29(7):913-7. PubMed ID: 26164356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    ; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
    N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
    Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
    Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
    Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
    Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.